| Literature DB >> 33755027 |
Peng Zhao1, Illhoi Yoo1,2, Syed H Naqvi3.
Abstract
BACKGROUND: Existing readmission reduction solutions tend to focus on complementing inpatient care with enhanced care transition and postdischarge interventions. These solutions are initiated near or after discharge, when clinicians' impact on inpatient care is ending. Preventive intervention during hospitalization is an underexplored area that holds potential for reducing readmission risk. However, it is challenging to predict readmission risk at the early stage of hospitalization because few data are available.Entities:
Keywords: 30-day; all-cause; early detection; machine learning; patient readmission; predictive model; risk factors; unplanned
Year: 2021 PMID: 33755027 PMCID: PMC8077543 DOI: 10.2196/16306
Source DB: PubMed Journal: JMIR Med Inform
Figure 1The variables used to develop the models.
Feature representation and value types.
| Type and category | Representation | Data type | |||
|
| |||||
|
| Diagnosis | CCSa | Count | ||
|
| Procedure | CCS | Count | ||
|
| Laboratory test | Name | Count | ||
|
| Vital sign | Name | Count | ||
|
| Medication | Generic name | Count | ||
|
| Utilization | Name | Count | ||
|
| |||||
|
| Demographic | Name | Discretized age, race, sex, payer, region, or rurality | ||
|
| Medication | Generic name | Ordered or not | ||
|
| Laboratory test | Name | Latest result is abnormal or not | ||
|
| Vital sign | Name | Latest result is abnormal or not | ||
aCCS: Clinical Classifications Software.
Demographic information of the 96,550 patients included in the data set. The characteristics with the highest frequencies are indicated with italic text.
| Characteristic | Value, n (%) | ||||
|
|
| Readmission=yes | Readmission=no | ||
| Total | 11,294 (11.7) | 85,256 (88.3) | |||
|
| |||||
|
| 18-34 | 930 (8.2) | 13,242 (15.5) | ||
|
| 35-49 | 1525 (13.5) | 12,541 (14.7) | ||
|
| 50-64 | 3116 (27.6) | 21,559 (25.3) | ||
|
|
|
| |||
|
| ≥80 | 2343 (20.7) | 15,280 (17.9) | ||
|
| |||||
|
|
|
|
| ||
|
| Male | 5328 (47.2) | 35,637 (41.8) | ||
|
| |||||
|
| African American | 2612 (23.1) | 16,248 (19.1) | ||
|
|
|
|
| ||
|
| Other | 932 (8.3) | 7323 (8.6) | ||
*Italicized text represents majority in the group.
10-fold cross-validation AUCs of the candidate models on the development set.
| Model | 10-fold cross-validation AUCa, mean (SD) |
| Logistic regression | 0.750 (0.005) |
| Naïve Bayes | 0.730 (0.006) |
| Alternating decision tree | 0.730 (0.010) |
| Random forest | 0.734 (0.006) |
| XGBoostb | 0.753 (0.007) |
| Neural network | 0.746 (0.004) |
aAUC: area under the receiver operating characteristic curve.
bXGBoost: extreme gradient boosting.
Performance of the candidate models and baseline models on the validation set. The best-performing parameters are indicated in italic text.
| Model | Optimal cutoff | Specificity | Precision | Recall | F1 measure | AUCa |
| Logistic regression | 0.157 | 0.642 | 0.857 | 0.729 | 0.773 | 0.741 |
| Naïve Bayes | 0.220 | 0.666 | 0.855 | 0.685 | 0.740 | 0.720 |
| Alternating decision tree | 0.298 | 0.662 | 0.857 | 0.705 | 0.755 | 0.732 |
| Random forest | 0.122 |
|
| 0.611 | 0.680 | 0.726 |
| XGBoostb | 0.175 | 0.611 | 0.856 |
|
|
|
| Neural network | 0.125 | 0.686 | 0.858 | 0.681 | 0.737 | 0.735 |
| HOSPITAL score | 4 | 0.564 | 0.838 | 0.694 | 0.745 | 0.688 |
| LACE index | 11 | 0.469 | 0.830 | 0.745 | 0.779 | 0.675 |
| LACE-rt index | 7 | 0.542 | 0.833 | 0.688 | 0.740 | 0.668 |
aAUC: area under the curve.
bXGBoost: extreme gradient boosting.
The 14 novel risk factors and 2 novel protective factors of readmission identified in the study.
| Risks or protective factors | Coefficient | Odds ratio (95% CI) | ||||||
|
| ||||||||
|
|
| |||||||
|
|
| 1 maintenance chemotherapy visit in the last year | 0.390 | <.001 | 1.476 (1.218-1.790) | |||
|
|
| |||||||
|
|
| 1 abnormal lymphocyte count test in the last year | 0.221 | <.001 | 1.247 (1.144-1.359) | |||
|
|
| ≥2 abnormal lymphocyte count tests in the last year | 0.228 | .001 | 1.257 (1.091-1.447) | |||
|
|
| 1 abnormal monocyte count test in the last year | 0.182 | .005 | 1.199 (1.056-1.362) | |||
|
|
| ≥2 abnormal monocyte percent tests in the last year | 0.316 | <.001 | 1.371 (1.178- 1.596 | |||
|
|
| 1 abnormal serum calcium quantitative test in the last year | 0.226 | <.001 | 1.254 (1.107-1.420) | |||
|
|
| ≥2 abnormal serum calcium quantitative tests in the last year | 0.297 | .001 | 1.345 (1.122-1.612) | |||
|
|
| |||||||
|
|
| 1 albuterol ipratropium order in the last year | 0.071 | .02 | 1.073 (1.010-1.141) | |||
|
|
| ≥2 albuterol ipratropium orders in the last year | 0.145 | .003 | 1.157 (1.052-1.272) | |||
|
|
| 1 cefazolin order in the last year | –0.123 | .001 | 0.884 (0.822-0.950) | |||
|
| ||||||||
|
|
| |||||||
|
|
| Index admission to hospital in Northeast census region | 0.365 | <.001 | 1.441 (1.345-1.543) | |||
|
|
| |||||||
|
|
| Gabapentin ordered at index admission | 0.162 | <.001 | 1.176 (1.113-1.243) | |||
|
|
| Ondansetron ordered at index admission | 0.105 | <.001 | 1.111 (1.057-1.168) | |||
|
|
| Polyethylene glycol 3350 ordered at index admission | 0.073 | .01 | 1.076 (1.017-1.139) | |||
|
|
| Cefazolin ordered at index admission | –0.147 | <.001 | 0.863 (0.798-0.934) | |||
|
|
| |||||||
|
|
| ≥16 abnormal laboratory test results at index admission | 0.140 | .005 | 1.151 (1.043-1.269) | |||